Why did ALZN's stock price hit a 52-week low?

Alzamend Neuro (ALZN) stock hit a 52-week low of $1.81 on September 16, 2024, can be attributed to several key factors: 1. **Financial Performance**: The company's financial performance has been under pressure, with a significant decline in stock price reflecting investor concerns about its earnings capability. ALZN's stock price fell by -6.69% from August 28 to November 13, hitting a low on November 13, which may indicate market disappointment with the company's inability to generate positive earnings. 2. **Lack of Positive Earnings**: ALZN has not shown positive earnings over the past year, with the most recent estimate for the next quarter being -$54.00. This consistent performance below expectations leads to a loss of investor confidence, resulting in downward pressure on the stock price. 3. **Industry Challenges**: As a biopharmaceutical company, ALZN faces unique challenges, including rigorous regulatory environments and high competition. These factors have likely contributed to the company's difficulties in maintaining investor confidence and achieving profitability. In summary, the combination of poor financial performance, lack of positive earnings, and industry-specific challenges has led to a significant decline in ALZN's stock price, hitting a 52-week low. |code|Ticker|Name|Date|Percentage Change|market_code| |---|---|---|---|---|---| |ALZN|ALZN.O|Alzamend Neuro|20250801|-2.2222|186|